References
- GuertinJRMitchellDAliFLeLorierJBias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drugClinicoecon Outcomes Res2015749750326504402
- PortaMA Dictionary of Epidemiology5th edOxford, EnglandOxford University Press2008
- Health CanadaDrugs and Health Products. Patent Register Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/patregbrev/index-eng.phpAccessed November 19, 2015
- VernazNHallerGGirardinFPatented drug extension strategies on healthcare spending: a cost-evaluation analysisPLoS Med2013106e100146023750120
References
- GuertinJRMitchellDAliFLeLorierJBias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drugClinicoEcon Outcomes Res2015749750326504402
- Task Force on Principles for Economic Analysis of Health Care TechnologyEconomic analysis of health care technology: a report on principlesAnn Intern Med199512361707762918
- Guidelines for the Economic Evaluation of Health Technologies: Canada3rd edOttawa, CanadaCanadian Agency for Drug and Technologies in Health2006
- Canadian Agency for Drugs and Technologies in HealthUpdate of Guidelines for the Economic Evaluation of Health Technologies: Canada Available from: https://www.cadth.ca/about-cadth/how-we-do-it/methods-and-guidelines/guidelines-for-the-economic-evaluation-of-health-technologies-canada/updateAccessed on December 3, 2015